Invention Grant
- Patent Title: MELK regulation for the treatment of breast cancer
- Patent Title (中): MELK治疗乳腺癌的规定
-
Application No.: US14759889Application Date: 2014-01-08
-
Publication No.: US09540619B2Publication Date: 2017-01-10
- Inventor: Xizhong Huang , Jean J. Zhao , Junxia Min , Yubao Wang
- Applicant: NOVARTIS AG , DANA-FARBER CANCER INSTITUTE, INC.
- Applicant Address: CH Basel US MA Boston
- Assignee: Novartis AG,Dana-Farber Cancer Institute, Inc.
- Current Assignee: Novartis AG,Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: CH Basel US MA Boston
- Agency: Brinks Gilson & Lione
- International Application: PCT/US2014/010724 WO 20140108
- International Announcement: WO2014/110163 WO 20140717
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12N9/12 ; A61K38/12 ; A61K31/7088 ; C12Q1/68

Abstract:
Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided.
Public/Granted literature
- US20150353935A1 MELK Regulation for the Treatment of Breast Cancer Public/Granted day:2015-12-10
Information query
IPC分类: